PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
Emmanuelle Moraes RibeiroKathy-Ann SeckerAna-Maria NitulescuRebekka SchairerHildegard KeppelerAnton WesleHannes SchmidAnita SchmittBrigitte NeuberDaniela ChmiestSilvia PodaviniMelanie MärklinBoris KlimovichMichael SchmittFulya KorkmazClaudia LengerkeCorina SchneidawindDominik SchneidawindPublished in: Journal for immunotherapy of cancer (2024)
In this work, we demonstrate that CAR-iNKT cells are a powerful cytotherapeutic option to prevent or treat relapse while potentially reducing the risk of GVHD after allogeneic HCT.